Gradalis, Inc.

Gradalis, Inc.

Leading a new way to fight cancer

Founded 2003

Carrollton, United States 24 employees Grant Biotechnology, Health Care +1

Gradalis is a late-stage clinical biotechnology company developing immunotherapies for multiple cancer indications including an upcoming Phase 3 registration trial in patients with ovarian cancer. The company’s proprietary bi-shRNA therapy platform, which has been proven in its clinical studies, can be utilized to silence a broad range of genes and is applicable to multiple cancer types. About Vigil Vigil® is the first cellular therapy to show positive survival benefits in a randomized controlled clinical study of patients with solid tumors. Vigil is a self-navigating cellular immunotherapy that addresses the major deficits of leading cancer treatments. Vigil uses all of a patient’s tumor-related antigens to identify cancer cells and then enhances the training of the immune system to recognize and attack those cells. Gradalis’s proprietary bi-shRNA platform accomplishes this via three key functions: (1) it blocks furin, the enzyme that generates the immunosuppressive cytokines TGF beta types 1 and 2; (2) it activates effector cells including antigen-presenting dendritic cells and CD8+ T cells via the production of GM-CSF; and (3) it induces an immune response to the full complement of neo-antigens from the patient’s tumor via intradermal administration. In a Phase 2b trial, Vigil showed a positive trend in the primary endpoint of recurrence-free survival in the overall population and a significant improvement in recurrence-free survival and overall survival in a pre-planned subgroup analysis of Stage III/IV newly diagnosed ovarian cancer patients with the BRCA wild type (BRCA-wt) molecular profile. The company is preparing to initiate a clinical study intended for product registration in patients in this subgroup. Additionally, Phase 1 results in an all-comer trial have shown positive signals of activity in multiple tumor types.

FAQ About Gradalis, Inc.

Leading a new way to fight cancer

Gradalis, Inc. was founded in 2003.

Gradalis, Inc. is headquartered in Carrollton, United States.

Gradalis, Inc. operates in Biotechnology, Health Care and Manufacturing.

Gradalis, Inc. has approximately 24 employees.

Top alternatives and competitors to Gradalis, Inc. include ImmunoCellular Therapeutics Ltd, Northwest Biotherapeutics, Lytix Biopharma, Genenta Science (Nasdaq: GNTA), CEL-SCI Corporation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Gradalis, Inc. and ImmunoCellular Therapeutics Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Gradalis, Inc.

Gradalis, Inc. Alternatives & Competitors

FAQ About Gradalis, Inc.